Health Carerss

Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny

Tickers in this article: MNK MYL VRX

Short-seller Andrew Left says Mallinckrodt has long been gaming the system on its Acthar Gel drug.

08/25/16 - 10:39 AM EDT

Chinese Plasma Maker China Biologic a Solid Addition for a Portfolio

Tickers in this article: CBPO

This little-known, Beijing-based drug company is benefiting from accelerating demand for blood substitutes.

08/11/16 - 07:26 AM EDT

Bristol-Myers Offers Strong Risk/Reward Trade Now

Bristol-Myers Offers Strong Risk/Reward Trade Now

Tickers in this article: BMY

Wise investors should not follow analysts who have downgraded Bristol-Myers Squibb, but should instead purchase the stock on sale.

08/09/16 - 07:01 AM EDT

Here's Why Allergan's Earnings Report Could Be Lackluster

Here's Why Allergan's Earnings Report Could Be Lackluster

Tickers in this article: AGN PFE

This drug giant could be on the verge of disappointing investors. Here's why you need to be wary ahead of its operating results on Monday.

08/07/16 - 02:25 PM EDT

Obamacare Still Sickly, After All These Years

Obamacare Still Sickly, After All These Years

Tickers in this article: XPH UNH

Two new reports show how the U.S. healthcare system is falling short, despite six years of Obamacare. Simon Constable explains what's happening and what it means for investors.

08/07/16 - 01:20 PM EDT

Biotech Stock Mailbag: Ionis, Trust Issues and 'Oops! Don't Look at That Slide Deck'

Biotech Stock Mailbag: Ionis, Trust Issues and 'Oops! Don't Look at That Slide Deck'

Tickers in this article: IONS BIIB

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

08/05/16 - 07:01 AM EDT

Why Allergan Can Head Higher Despite a Messy Quarter -- Plus Jim Cramer's Take

Why Allergan Can Head Higher Despite a Messy Quarter -- Plus Jim Cramer's Take

Tickers in this article: AGN PFE TEVA

Allergan stock is down 19% year to date, but probably not for long. Over the next year, Allergan could trade much higher.

08/05/16 - 05:45 AM EDT

Valeant Could Lower Expectations Even Further

Valeant Could Lower Expectations Even Further

Tickers in this article: VRX

Analysts say shareholders may find more bad news on Valeant's earnings call next week.

08/02/16 - 01:21 PM EDT

Where Will a Healthy Zimmer Biomet Turn Next for Acquisitions?

Where Will a Healthy Zimmer Biomet Turn Next for Acquisitions?

Tickers in this article: ZBH JNJ NUVA OFIX

Zimmer's return to growth is fueling acquisition thoughts by analysts. There are a number of possibilities.

07/29/16 - 06:20 PM EDT

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs

Tickers in this article: PBYI RLYP XBIT

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

07/29/16 - 07:01 AM EDT

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Tickers in this article: BIIB LLY JNJ ABBV ELN PFE

A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.

07/27/16 - 08:00 AM EDT

Cerner Could Be a Prized Asset for IBM

Cerner Could Be a Prized Asset for IBM

Tickers in this article: CERN IBM GOOGL MCK MSFT VCRA

The health care IT firm is viewed as a 'crown jewel' but may still be too large of an asset for logical buyers to get comfortable with.

07/27/16 - 06:02 AM EDT

Wait for Another 10% Drop In Gilead Before Buying

Wait for Another 10% Drop In Gilead Before Buying

Tickers in this article: GILD

The stock is poised to test support at around $78 per share, or 10% lower. At that point, Gilead stock is safe to buy. Anything in between is trap.

07/26/16 - 06:17 AM EDT

Take Profits in PetMed, Then Wait for a Pullback

Take Profits in PetMed, Then Wait for a Pullback

Tickers in this article: PETS SPX VHT

At best, the stock should be priced at around $18, or 12% lower.

07/26/16 - 05:57 AM EDT